.rll-youtube-player .play{--wpr-bg-b61896a5-035b-4a50-b247-da4e855b9770: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Krasg12c mutations

KRASG12C mutations

Jan 08, 2024

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles

Feb 12, 2025

Newsletter/Whitepaper

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

KRASG12C mutations

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

Editor Picks